Topotecan plus carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a meta-analysis of randomized controlled trials
Topotecan plus carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a meta-analysis of randomized controlled trials
复制标题
拓扑替康联合卡铂和紫杉醇一线治疗晚期卵巢癌：随机对照试验的荟萃分析
DOI：
10.1179/1120009x12z.0000000002
复制
发表时间：
2012-04
期刊：
影响因子：
--
通讯作者：
张辉
中科院分区：
文献类型：
--
作者：
张辉
摘要目的：评价拓扑替康联合卡铂和紫杉醇一线治疗晚期上皮性卵巢癌的疗效。方法：采用随机效应模型进行Meta分析。结果：4项随机对照试验，共3632例患者被确定并纳入荟萃分析。拓扑替康联合卡铂和紫杉醇治疗组与卡铂和紫杉醇治疗组的无进展生存期（P = 0·400）、总生存期（P = 0·502）和总缓解率（P = 0·953）无显著差异。 拓扑替康联合卡铂和紫杉醇组3 - 4级白细胞减少（P = 0.024）、中性粒细胞减少（P <0.001）、贫血（P <0.001）和血小板减少（P <0.001）的发生率明显较高。 两组3-4级恶心（P = 0.352）和呕吐（P = 0.092）发生率无显著性差异。 结论：拓扑替康联合卡铂和紫杉醇不能改善晚期卵巢癌的生存结局，并引起更多的血液学毒性。
Abstract Objective: To evaluate whether the addition of topotecan can improve the efficacy of carboplatin and paclitaxel in first-line treatment of advanced epithelial ovarian cancer. Methods: Meta-analysis was performed using a random effects model. Results: Four randomized controlled trials with a total of 3632 patients were identified and included in the meta-analysis. No significant differences were observed in terms of progression-free survival (P = 0·400), overall survival (P = 0·502) and overall response rate (P = 0·953) between patients treated with topotecan plus carboplatin and paclitaxel versus carboplatin and paclitaxel. However, there were significantly higher rates of grade 3–4 leucopenia (P = 0·024), neutropenia (P<0·001), anaemia (P<0·001), and thrombopenia (P<0·001) in the topotecan plus carboplatin and paclitaxel group. No significant differences were observed in grade 3–4 nausea (P = 0·352) and vomiting (P = 0·092) between these two groups. Conclusion: Topotecan plus carboplatin and paclitaxel did not improve survival outcomes and caused more haematological toxicity for advanced ovarian cancer.
登录
查看更多内容
DOI：
10.1634/theoncologist.7-suppl_5-46
发表时间：
2002-10
期刊：
The oncologist
影响因子：
--
作者：
R. Coleman
通讯作者：
R. Coleman
影响因子：
45.3
作者：
Bookman, MA;Malmström, H;Fields, SZ
通讯作者：
Fields, SZ
影响因子：
10.3
作者：
du Bois, A;Lück, HJ;Pfisterer, J
通讯作者：
Pfisterer, J
DOI：
10.1016/s0084-3873(09)79574-4
发表时间：
2009
期刊：
Yearbook of Medicine
影响因子：
--
作者：
J. Thigpen
通讯作者：
J. Thigpen
影响因子：
4.7
作者：
G. Bolis;G. Scarfone;A. Villa;F. Parazzini
通讯作者：
G. Bolis;G. Scarfone;A. Villa;F. Parazzini